Syndax Pharmaceuticals, Inc. Capital Expenditures
Syndax Pharmaceuticals, Inc. (SNDX) reported Capital Expenditures of $187.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-02-26
- Syndax Pharmaceuticals, Inc. payments to acquire property, plant, and equipment for the quarter ending 2018-12-31 was $14.00K, a 66.67% decline year-over-year.
- Syndax Pharmaceuticals, Inc. payments to acquire property, plant, and equipment for the quarter ending 2018-09-30 was $0.00.
- Syndax Pharmaceuticals, Inc. payments to acquire property, plant, and equipment for the quarter ending 2018-06-30 was $0.00.
- Syndax Pharmaceuticals, Inc. payments to acquire property, plant, and equipment for the quarter ending 2018-03-31 was $173.00K.
- Syndax Pharmaceuticals, Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $187.00K.
- Syndax Pharmaceuticals, Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $0.00.
- Syndax Pharmaceuticals, Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $0.00.
- Syndax Pharmaceuticals, Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2025-12-31 | $187.00K 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-02-27 | |||
| 2021-12-31 | $129.00K 10-K · filed 2024-02-27 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-28 | |||
| 2018-12-31 | $14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $14.00K derived: sum of 2 quarters · filed 2021-03-12 | $14.00K derived: sum of 3 quarters · filed 2021-03-12 | $187.00K 10-K · filed 2021-03-12 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $0.00 derived: sum of 2 quarters · filed 2019-11-07 | $173.00K 10-Q · filed 2019-11-07 | $215.00K derived: sum of 4 quarters · filed 2020-03-05 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $173.00K 10-Q · filed 2019-08-07 | $215.00K derived: sum of 3 quarters · filed 2020-03-05 | |
| 2018-03-31 | $173.00K 10-Q · filed 2019-05-08 | $215.00K derived: sum of 2 quarters · filed 2020-03-05 | ||
| 2017-12-31 | $42.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $84.00K 10-K · filed 2020-03-05 | ||
| 2017-09-30 | $42.00K 10-Q · filed 2018-11-05 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $55.00K derived: sum of 2 quarters · filed 2019-03-07 | $128.00K derived: sum of 3 quarters · filed 2019-03-07 | $261.00K 10-K · filed 2019-03-07 |
| 2016-09-30 | $55.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $128.00K derived: sum of 2 quarters · filed 2017-11-08 | $261.00K 10-Q · filed 2017-11-08 | $292.00K derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-06-30 | $73.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $206.00K 10-Q · filed 2017-08-10 | $237.00K derived: sum of 3 quarters · filed 2018-03-08 | $250.00K derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-03-31 | $133.00K 10-Q · filed 2017-05-09 | $164.00K derived: sum of 2 quarters · filed 2018-03-08 | $177.00K derived: sum of 3 quarters · filed 2018-03-08 | |
| 2015-12-31 | $31.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $44.00K derived: sum of 2 quarters · filed 2018-03-08 | $49.00K 10-K · filed 2018-03-08 | |
| 2015-09-30 | $13.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $18.00K 10-Q · filed 2016-11-14 | ||
| 2015-06-30 | $5.00K 10-Q · filed 2016-08-15 | |||
| 2014-12-31 | $4.00K 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |